SB 814 - This act requires health benefit plan enrollees' deductible payment or coinsurance amount for prescription insulin drugs to be calculated at the point of sale, and based on a price that is reduced by an amount equal to at least 100% of all rebates received, or to be received, in connection with the dispensing or administration of the drug.

The act shall not require a health carrier or its agents to reveal information regarding the actual amount of rebates a carrier receives on a product, manufacturer, or pharmacy-specific basis. The act also provides confidentiality protections, as specified in the act, which the carriers shall follow as well as impose on any third party that performs health care or administrative services on behalf of the carrier and may receive or have access to rebate information.

This act contains a severability clause.

This act is similar to SB 112 (2021), identical to SB 962 (2020), and similar to HCS/HB 2527 (2020).


Return to Main Bill Page